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Improved efﬁcacy of targeted kinase inhibitors may be achieved by 
targeting the dominant activating mutations present.
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Background: MET belongs to the semaphorin superfamily of signaling 
proteins, containing three protein families (semaphorins, plexins, MET 
and RON) that have central roles in cell signaling. The MET receptor 
tyrosine kinase is involved in regulating cell growth/proliferation, sur-
vival, angiogenesis, cell scattering, cell motility and migration. Muta-
tions in MET have been identiﬁed in various human cancers including 
lung cancer and papillary renal cell carcinomas. MET mutations occur 
within the extracellular seven-blade β-propeller fold sema domain 
(E168D, L229F, S325G, N375S), the juxtamembrane domain (R988C, 
T1010I), and the kinase domain (M1268T). We hypothesized that these 
mutations would have differential effects on the kinase inhibition.
Methods: We modeled the various MET mutations from different 
functional domains of the receptor using Cos-7 transfection cell system 
to determine their effect on MET signaling and sensitivity to a selec-
tive MET kinase inhibitor SU11274. Sensitivity to SU11274 inhibi-
tion was assayed by phospho-immunoblotting using phospho-speciﬁc 
antibody against the major tyrosine kinase phosphorylation epitopes 
pY1234/1235 of the MET kinase in vitro.
Results: First, we identiﬁed that mutations in the sema and juxta-
membrane domain were activating as deﬁned by ligand-independent 
constitutive receptor activation. SU11274 was capable of inhibiting 
ligand induced signaling through the wild-type MET as well as mutant 
MET receptors harboring mutations in the sema, juxtamembrane and 
tyrosine kinase domain. However, SU11274 inhibition of mutant MET 
was mutation-dependent, with the juxtamembrane domain mutations 
R988C and T1010I resulting in a receptor form that was less sensitive 
to SU11274. Mutations in the sema and kinase domain also resulted 
in varying sensitivity to inhibition by SU11274 inhibition. Interest-
ingly, the kinase domain L1243R mutation in MET (homologous to the 
epidermal growth factor receptor L858R-EGFR sensitizing muta-
tion in lung cancer) substantially sensitized the mutant MET receptor 
to SU11274 inhibition with complete p-MET inhibition at 0.5 μM 
compared to 5 μM as in wild type. On the other hand, the activating 
M1268T mutation in the kinase domain was less sensitive to SU11274 
than the wild type receptor.
Conclusion: Mutations in the sema and juxtamembrane domain 
of MET result in receptor activation. The small molecule inhibi-
tor SU11274 is active against wild type and various mutated MET 
receptor. Further studies to characterize the signaling effects and the 
mechanism of sensitivity and resistance of MET mutations to speciﬁc 
inhibitors are crucial in the successful development of therapeutic MET 
inhibitors in personalized cancer therapy.
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Introduction: One of the basic exogenous factors of lung cancer 
incidence is smoking. On the other hand, hereditary predisposition in 
particular, genetic polymorphism of enzymes, plays an important part 
in development of oncologic diseases. The important role in oncopath-
ology emergence is assigned to glutathiontransferases (GST), because 
these enzymes are involved in detoxication of reactive metabolites. 
Mutations in detoxication genes are also known to be accompanied by 
the change in the cytogenetic parameter level, which are attributed to 
cytogenetic markers of early carcinogenesis stages. 
The interrelation between GSTT1 polymorphism and the chromosome 
aberrations level was analyzed in peripheral blood lymphocytes (PBL) 
and lung tissues of non-small-celled lung cancer (NSCLC) patients.
Materials and Methods: The frequencies of GSTT1 gene polymor-
phic alleles were investigated using a polymerase chain reaction in 49 
NSCLC patients. 
For cytogenetic research the interphase analysis of somatic cells 
without cultivation was used. The frequency of cells with micronuclei 
was estimated in PBL and in lung cells from nontumour tissues of lung 
cancer patients.
Results and Discussion: Analysis of GSTT1-gene polymorphism has 
shown that GSTT1(-) genotype occurred signiﬁcantly more often in 
NSCLC patients (26,6%) than in the control (4%). The study on genetic 
GSTT1 polymorphism with due account of the smoking factor has 
demonstrated that the GSTT1(-) genotype was observed with statistical 
signiﬁcance 1,5-fold more often (36,4%) in the group of non-smoking 
patients than among smoking ones - 23,7%. It is interesting that such 
regularity was revealed by other researchers for many others genes of 
xenobiotic biotransformation enzymes. 
The obtained data of the cytogenetic analysis in different tissues 
of oncologic patients were estimated by us with due account of the 
smoking factor and the genotype. In non-smoking patients, the level 
of cells with micronuclei in PBL was twice as high in the patients 
with the GSTT1(+) genotype (0,43±0,13%) as in the patients with the 
GSTT1(-) genotype (0,21±0,07%). In smoking patients the level of 
cells with micronuclei in PBL did not differ signiﬁcantly in carriers 
of the GSTT1(+) genotype (0,32±0,05%) and the GSTT1(-) genotype 
(0,29±0,09%). Some authors associate the low number cells with chro-
mosome aberrations in smoking patients and GSTT1 (-) carriers with 
higher enzyme expression, involved in repair of DNA damages.
Statistically signiﬁcant excess of the group average level of cells with 
micronuclei was shown in nontumoral tissue of smoking patients 
with the GSTT1(-) (0,57±0,08%) over those with the GSTT1(+) 
(0,33±0,04%). In non-smoking patients, the level of cells with 
micronuclei did not differ in GSTT1(-) - 0,30±0,02% and GSTT1(+)- 
0,38±0,14%. Damaging effect of tobacco smoke carcinogens directly 
on lung tissue in smokers is one of explanations of this fact that in 
combination with availability of mutant gene alleles of detoxication 
enzymes results in high probability of emerging cytogenetic injuries 
just in lung tissue. 
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Conclusions: The obtained results have shown the possible relation 
between the GSTT1 genotype and the level of chromosome aberrations 
in somatic cells of lung cancer patients. 
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Background: The clinical application of monoclonal antibodies has 
been well established for the treatment of various human cancers. 
However, there were a few reports which showed the effectiveness of 
antibody therapy against lung cancer. In the present study, we report a 
novel cell surface antigen which was identiﬁed by SEREX method by 
using the antibody (Ab) derived from tumor-inﬁltrating B lymphocytes 
(TIB).
Methods: A904L, a lung large cell carcinoma cell line, was established 
from patient A904. The surgically resected lung cancer specimens of 
the patient was xenotransplanted into SCID mice. SCID mice engrafted 
with the lung cancer were bled by retro-orbital venipuncture every 2 
weeks and the amount of human immunoglobulin produced from TIB 
in the blood was analyzed by ELISA. A cDNA library was constructed 
from A904L cells and immunoscreening was performed by SEREX 
method by using IgG derived from TIB. 
Results: As a result of the cDNA library screening, 22 different antigen 
genes were isolated. A homology search through BLAST database 
revealed that the 22 antigen genes included 13 function-known and 9 
function-unknown genes. Identiﬁed antigens were sequenced and 4 of 
these antigens had extracellular domain. We designated one of these 
antigens as UOEH-LC-1. The mRNA expression of UOEH-LC-1 was 
investigated in lung cancer cell lines, normal tissues and tissue speci-
mens of lung cancer, using quantitative RT-PCR. UOEH-LC-1 was 
overexpressed in 5 of 11 (45.5%) lung cancer cell lines and also was 
overexpressed in 9 of 15 (60%) lung cancer tissues compared with the 
paired normal lung tissues. mRNA of UOEH-LC-1 was expressed in 
heart, kidney, liver, prostate, testis and thyroid gland among the panel 
of 20 normal tissues. Immunohistochemical evaluation of UOEH-LC-
1 was performed in the lung cancer tissue specimens by using rabbit 
polyclonal Ab against UOEH-LC-1. Seven out of 28 (25.0%) lung 
cancer specimens demonstrated positive staining on the cell surface. 
Flow cytometry analysis using the polyclonal Ab revealed positive 
staining on lung cancer cell lines which were positive expression 
of mRNA of UOEH-LC-1, however negative staining for a cell line 
with negative mRNA expression of UOEH-LC-1. The suppressive 
effect of polyclonal Ab was examined in SCID mice model xenotrans-
planted with UOEH-LC-1 positive lung cancer cell line (A904L). The 
administration of anti-UOEH-LC-1 Ab inhibited the growth of A904L. 
Complement-dependent-cytotoxicity (CDC) of anti-UOEH-LC-1 Ab 
was observed against UOEH-LC-1 positive 2 cell lines, but not against 
a UOEH-LC-1 negative lung cancer cell line. One possible mechanism 
of an anti-tumor effect of anti-UOEH-LC-1 Ab was mediated by the 
CDC activity. 
Conclusions: UOEH-LC-1 was overexpressed on the cell surface of 
lung cancer. Furthermore, the antibody against UOEH-LC-1 had anti-
tumor activity both in vitro and in vivo. The growth inhibitory effects 
of the Ab on lung cancer indicates the usefulness of UOEH-LC-1 as an 
effective target for antibody-based immunotherapy.
P2-142 BSTB: Tumor and Cell Biology Posters, Tue, Sept 4 
Female adenocarcinoma expresses higher levels of estrogen 
receptors
Nakata, Masao Shimizu, Katsuhiko Hayama, Makio Hirami, Yuji 
Tanemoto, Kazuo 
Division of Thoracic and Cardiovascular Surgery, Kawasaki Medical 
School, Kurashiki, Japan
Background: It has been reported that there are several gender-associ-
ated differences in clinicopathological features of non-small cell lung 
cancer (NSCLC). The aim of this study was to measure the relative 
expression levels of estrogen receptor (ER) mRNA in NSCLC tissue, 
and to characterize the role of estrogen in gender differences. 
Methods: The ER mRNA expression levels in 20 parafﬁn-embedded 
samples of surgically resected NSCLC tissue were retrospectively de-
termined by RT-PCR. The ER mRNA expression levels were prospec-
tively measured in snap-frozen materials of both lung cancer tissue and 
normal lung in patients with adenocarcinoma. In both studies, the gene 
expression levels were determined as the relative values to the expres-
sion level of GAPDH. 
Results: In parafﬁn-embedded materials of NSCLC, the ERα mRNA 
expression level was signiﬁcantly higher in females (p=0.0003, versus 
males), non-smokers (p=0.0001, versus former or current-smokers), 
and adenocarcinoma (p=0.003, versus non-adenocarcinoma). The 
ER β mRNA expression level was signiﬁcantly higher in females 
(p=0.02, versus males) and non-smokers (p=0.02, versus former or 
current-smokers). A high expression level of ERα was associated with 
well-differentiated adenocarcinoma of females. In snap-frozen normal 
lung tissues, the ERα mRNA expression levels in males (n=4) and in 
females (n=3) were 9.85±12.80×10-3 and 8.90±5.90×10-3, respectively. 
On the other hand, the ERα mRNA expression levels in adenocarci-
noma tissue had the tendency to be higher in females than in males 
(15.87±22.57×10-3 versus 6.40±11.0×10-3). 
Conclusions: ERs were highly expressed in female pulmonary adeno-
carcinoma tissue. The results suggest that estrogens play a role in the 
development of female pulmonary adenocarcinoma, and are associated 
with the gender-differences in NSCLC. 
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The Fas/FasL system is a primary mediator of apoptosis. It plays an im-
portant role in the development of lung cancer. Osteoprotegerin (OPG) 
blocks endothelial cell apoptosis through binding to TRAIL (TNF 
related apoptosis inducing ligand). Elevated serum levels of soluble Fas 
(sFas), soluble FasL (sFasL) and OPG have been observed in patients 
with many kinds of cancer. The dates about levels of sFas, sFasL and 
OPG in lung cancer are poor. The present study was carried out to ana-
